Aerial BioPharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development

MORRISVILLE, N.C.--(BUSINESS WIRE)--Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

MORE ON THIS TOPIC